A new study has found that most individuals who are diagnosed with one mental health condition may find that they also have other psychiatric conditions. The study discovered that a number of mental health conditions share some genetic similarities, and this finding explains why multiple conditions are common among individuals suffering from psychiatric disorders.
Over one-half of individuals with a mental illness often have two or three conditions, with almost one-third suffering from four or more conditions. This makes it harder for clinicians to identify and treat these indications. However, this new discovery may help researchers develop new therapies for mental comorbidities and new ways to diagnose mental health conditions.
University of Colorado’s Andrew Grotzinger, the lead author of the study, stated in a university news release that the research was enabling progress toward the creation of a diagnostic manual that better mapped what was actually happening in an individual’s body biologically.
For their research, the scientists carried out a genetic analysis of 11 major mental health conditions, including post-traumatic stress disorder, schizophrenia, problematic alcohol use, bipolar disorder, autism, major depressive disorder, attention-deficit/hyperactivity disorder, Tourette syndrome, obsessive-compulsive disorder, anorexia nervosa and anxiety disorder.
While there is no set of genes linked to all of these disorders, the researchers did find that some subsets possess genetic similarities. These subsets include anxiety and major depressive disorder; obsessive-compulsive disorder and anorexia nervosa; and schizophrenia and bipolar disorder. For instance, 70% of the genetic signal linked to schizophrenia is also linked to bipolar disorder. However, the researchers noted that under current diagnostic guidelines, individuals weren’t typically diagnosed with both mental illnesses.
The researchers also discovered strong shared genetics between obsessive-compulsive disorder and anorexia, explaining that individuals who were genetically predisposed to a low BMI or a smaller body type also tended to be genetically predisposed to these mental conditions.
In total, the scientists identified more than 150 genetic variants shared across various mental health conditions, including variants that they know affect specific types of brain cells.
Grotzinger, who is an assistant professor of neuroscience and psychology at the University of Colorado at Boulder, explained that more studies were needed to pinpoint the effects of the variants they identified. He then noted that better understanding the genetics that underlie these disorders may also offer comfort to some individuals with multiple mental health conditions.
The study’s findings were reported in the “Nature Genetics” journal.
The discovery that genetic profiles explain why patients are often diagnosed with more than one mental disorder makes a strong case for the new lines of treatment that are being developed from new active pharmaceutical ingredients like psilocybin by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN)
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
Enormous resources are being channeled into studying different ways to support the immune system in its fight…
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…
David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…
Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…
High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…